UK flag Brexit: What We Are (And Aren't) Doing Get the Fool's analysis on what the UK leaving the EU means for investors

Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide.


Updates from The Motley Fool

Latest updates on Gilead Sciences from Fool.com.


Stock Performance

GILD vs. S&P 500 | 2 Year Performance
View Interactive GILD Charts
Sponsored by

Key Data Points

Primary metrics and data points about Gilead Sciences.
Current Price: $80.47
Prev Close: $83.37
Open: $81.17
Bid: $80.50
Ask: $80.87
Day's Range: $80.22 - $82.25
52wk Range: $80.22 - $123.37
Volume: 12,413,467
Avg Vol 8,603,473
Market Cap: $115.97B
P/E (ttm): 6.95
EPS (ttm): $12.00
Div & Yield: $1.72 (2.3%)

Company Rating

What our community thinks about Gilead Sciences.
CAPS Rating 5 out of 5
 
3585 Outperform
83 Underperform
CAPS All Stars
 
735 Outperform
14 Underperform

How do you think Gilead Sciences will perform against the market?



You pick for Gilead Sciences is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

John C. Martin, CEO

80% Approve

Based on 183 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Gilead Sciences.

Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers